jackpot wins casino slots LOUISVILLE, Ky. (AP) — Louisville has approved a five-year contract extension through June 2030 for athletic director Josh Heird, whose 2 1/2-year tenure has included the hirings of two men’s basketball coaches and football coach Jeff Brohm. The university’s Board of Trustees on Thursday authorized President Kim Schatzel to execute the deal, three days after the University of Louisville Athletic Association board approved the agreement. Heird was named interim AD in December 2021 before being elevated to the full-time job the following June. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a weekISRO to launch satellites to demonstrate docking, undocking of spacecraft

India advances toward becoming a 5 trillion dollars economy: PM ModiOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 12, 2024-- Takeda will host an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum of our Growth and Launch Products,” said Christophe Weber, Takeda chief executive officer. “The first three Phase 3 programs will read out in 2025, initiating a cadence of potential filings across multiple indications over the next several years.” The late-stage pipeline includes oveporexton (TAK-861), zasocitinib (TAK-279), rusfertide (TAK-121), mezagitamab (TAK-079), fazirsiran (TAK-999) and elritercept (TAK-226). Combined these programs have potential peak revenue 1 of $10B - $20B. Data from three Phase 3 programs is expected to read out in 2025: Filings for these three indications are expected in fiscal years 2025 and 2026. Five additional indication filings for late-stage programs are on pace for fiscal years 2027 through 2029: “Takeda has established an exciting, late-stage pipeline of transformative therapies that we believe will deliver value to our company and, most importantly, to the patients we serve around the world,” said Andy Plump, president of R&D at Takeda. “As we continue scaling our capabilities and maximizing R&D investment to deliver the late-stage pipeline, we are also progressing an exciting early-stage pipeline, supporting a cutting-edge research organization, and focusing on creative business development across our therapeutic areas to sustain Takeda’s future and continue to meet significant unmet patient needs.” The meeting includes the following presentations and speakers: Christophe Weber, President & CEO Andy Plump, President, Research and Development Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit and Head of Global Development Ramona Sequeira, President of Global Portfolio Division Chinwe Ukomadu, Head of Gastrointestinal and Inflammation Therapeutic Area Unit Ramona Sequeira, President of Global Portfolio Division Teresa Bitetti, President Global Oncology Business Unit P.K. Morrow, Head of Oncology Therapeutic Area Unit A live webcast of the meeting begins at 8:30 a.m. JST December 13 (6:30 p.m. EST December 12). Presentations are available on the where a video replay will be available following the meeting. Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit . For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at . Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. References in this press release to peak revenue potential ranges are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue potential ranges represent Takeda’s assessments of various possible future commercial scenarios that may or may not occur. References in this press release to PTRS are to internal estimates of Takeda regarding the likelihood of obtaining regulatory approval for a particular product in a particular indication. These estimates reflect the subjective judgment of responsible Takeda personnel and have been approved by Takeda’s Portfolio Review Committee for use in internal planning. This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Elritercept is included for reference only. Takeda entered into an exclusive license agreement with Keros for global rights, in all territories outside of mainland China, Hong Kong and Macau, to Elritercept. The closing of the transaction is subject to receipt of regulatory approval(s), expected in the first calendar quarter of 2025. Takeda does not currently have rights to Elritercept. ___________________________ 1 References in this presentation to peak revenue potential are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue ranges represent Takeda’s assessments of various possible future commercial scenarios that may or may not occur. View source version on : CONTACT: Investor Relations Christopher O’Reilly +81 (0) 90-6481-3412 Takeda Media Relations KEYWORD: MASSACHUSETTS UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: ONCOLOGY HEALTH NEUROLOGY CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Takeda Pharmaceutical Company Limited Copyright Business Wire 2024. PUB: 12/12/2024 05:30 PM/DISC: 12/12/2024 05:30 PM

Nigel Farage has hinted that there is "far more" to the scandal of banks closing or revoking the accounts of political figures than his dispute with Coutts last year. The Reform UK leader said the "debanking issue" is "about far more than what happened to me", in response to accusations made by a Silicon Valley businessman on Joe Rogan's podcast. The clip showed Marc Andreessen, the co-founder of Mosaic, the first widely-used web browser with a graphic user interface, alleging "tech founders, crypto founders and just generally [Biden's] political opponents" had been debanked. He added: "In the tech world, we've had like 30 founders debanked in the last four years", though didn't name the individuals supposedly affected. It was shared by X owner Elon Musk , alongside the message: "Did you know that 30 tech founders were secretly debanked?" Did you know that 30 tech founders were secretly debanked? https://t.co/gmnCir43XD While the podcast clip relates to the US market, which has seen cryptocurrency soar since Donald Trump 's election, Mr Farage implied a wider issue underlying his battle with a high-end bank in June 2023. The MP for Clacton-on-Sea claimed that Coutts, which is owned by NatWest , had closed his account because they disagreed with his political beliefs. The scandal led to the resignation of NatWest chief executive Alison Rose after she admitted a "serious error of judgement" in discussing Mr Farage's relationship with Coutts with a BBC journalist. Despite this, the bank maintained that the decision to shut down his account was lawful and based on commercial reasons. The UK's financial watchdog responded to the backlash by calling on banks to improve the way they treat so-called Politically Exposed Persons (PEPs). The Financial Conduct Authority found that most banks weren't imposing unnecessary checks and that while some political figures had been denied banking services or had their accounts closed, this was generally due to "financial crime reasons". The watchdog did identify a small number of cases were information requests for PEPs were "disproportionate", however. PEPs are generally subject to extra due diligence from banks because they pose a greater risk of abusing their position for financial gain, according to the FCA's 2017 guidance. In December 2023, the government changed the law to say UK PEPs should be treated as "inherently lower risk" than overseas politicians.Former US president Jimmy Carter passes away at 100

Telerehabilitation Systems Market to Expand by USD 532.9 Million (2024-2028), Rising Chronic Disease Cases Driving Revenue, AI Impacting Market Trends - TechnavioDFCC Bank Cards Bring Exciting Seasonal Savings and Rewarding Year-Round Benefits

Vikings stamp themselves as legitimate contenders with impressive victory over PackersStudents work diligently to finish the semester’s projects and study for finals. People throughout the region decorate their homes and businesses for the season and search for the perfect gifts for loved ones as the holidays approach. East Tennessee State University is gearing up for the biggest day of the semester – Commencement – but offers plenty of additional activities for students and the community in the month of December! The following listing includes events that are open to the public and are free unless otherwise noted: Music ETSU BLUE Down Home Takeover December 2-6, 7 p.m. each evening – Down Home, 300 W. Main Street This five-night musical event showcases all the bands in ETSU’s Bluegrass, Old-Time and Roots Music Studies program, which includes not only bluegrass and old-time ensembles, but country, a cappella and Celtic groups, as well. Tickets are $15 at the door; ETSU students with ID receive a discount. Holiday Concert: ‘For Auld Lang Syne’ December 7, performances at 4 p.m. and 7:30 p.m. – ETSU Foundation Grand Hall, Martin Center for the Arts Over 250 performers will take part in this beloved ETSU holiday tradition, including the ETSU Chorale, BucsWorth, East Tennessee Belles, Greyscale, Ascension, Percussion Ensemble and Faculty Brass Quintet, along with special guests Matthew Fisher, organ, and Joanna Seiber, harp. Tickets are $15-$25; free for ETSU students with ID. Theater/Cinema Bud Frank Cinema First Friday Screening: ‘Flow’ December 6, 7 p.m. – Bud Frank Theatre, Gilbreath Hall The Bud Frank Cinema’s First Friday Screening on Dec. 6 is “Flow,” a 2024 French film which opens for wide release the same day. “A wondrous journey, through realms natural and mystical, ‘Flow’ follows a courageous cat after his home is devastated by a great flood.” Bud Frank Cinema Film Screening: ‘Seven Samurai’ December 13, 7 p.m. – Bud Frank Theatre, Gilbreath Hall The Bud Frank Cinema and Tri-City Film Farm present a restoration of “Seven Samurai,” a 1954 film from Japan that tells the story of a 16 th -century village whose desperate inhabitants hire seven samurai warriors to protect them from invading bandits. ‘A Charlie Brown Christmas: Live on Stage’ December 17, 7 p.m. – ETSU Foundation Grand Hall, Martin Center for the Arts The timeless, award-winning animated television special by Charles M. Schulz comes to life in this faithful stage adaptation the whole family can enjoy. After the final bow, the audience is invited to join the Peanuts gang in singing traditional Christmas songs and carols. Tickets are $49.50-$139; limited seating is available. Fine Arts ‘FL3TCH3R Exhibit: Social and Politically Engaged Art’ Continuing through December 6, 9 a.m.-4:30 p.m. Monday-Friday – Reece Museum This annual exhibit, renowned for its exploration of contemporary social and political movements, features a diverse array of artworks addressing pressing global issues. ‘Stitch Together: The Social Seamstress in Southern Appalachia’ Continuing through January 10, 2025, 9 a.m.-4:30 p.m. Monday-Friday – Reece Museum The Reece Museum hosts this exhibit exploring the social connections of seamstresses by showcasing the fashion and clothing of the museum’s permanent collection. Holiday Fun and More Ice Skating at ETSU Various hours, Thursdays-Sundays through December 21 – University Commons ETSU’s beloved synthetic ice skating rink is open for the holiday season. This year, in partnership with Brightspeed, the rink is free to ETSU students, faculty and staff with valid ID and open to the community with a $5 skate rental for all ages. Hours are Thursdays and Fridays from 5-9 p.m., Saturdays from noon-7 p.m., and Sundays from 2-7 p.m. Great Lecture Series December 6, 2 p.m. – East Tennessee Room, D.P. Culp Student Center The Great Lecture Series celebrates and showcases ETSU faculty who have recently been promoted to full professor, giving them an opportunity to share their work with the broader community. Attendees of this installment will hear from Drs. Brian Johnston, John Rankin and Megan Quinn. Jacob’s Nature Park: As We See It! December 7, 1-2:30 p.m. – Jacob’s Nature Park at Sinking Creek, 1919 Ocala Street This event for the community features five 15-minute presentations by ETSU students on park-specific topics, such as poisonous plants, mushroom coolness, pollinator trivia and more. Interactive activities, games, giveaways and hands-on learning opportunities for all ages are included. ETSU Fall Commencement December 14, 10 a.m. and 2:30 p.m. – Ballad Health Athletic Center (Mini-Dome) ETSU celebrates its fall 2024 graduating class in two ceremonies (10 a.m. – Quillen College of Medicine, College of Public Health, College of Health Sciences and College of Arts and Sciences; and 2:30 p.m. – Clemmer College of Education and Human Development, College of Business and Technology and College of Nursing). Complete information for graduating students, guests and faculty is available on the Commencement website, etsu.edu/commencement , where livestreaming will be offered for those not attending in person. ETSU Alumni Arctic Adventures: Frost and Fun Skate Night December 19, 5-8:30 p.m. – University Commons The ETSU Alumni Association presents an evening of Frost and Fun at the ETSU synthetic ice skating rink sponsored by Brightspeed. Participants can enjoy popcorn and hot cocoa inside the first-floor lobby of the D.P. Culp Student Center, as well as limited-edition T-shirts, a visit from Bucky, giveaways and holiday music. To learn more about these and other events happening at ETSU, visit the university’s online calendar at etsu.edu/calendar/default.php . For disability accommodations, contact Disability Services at (423) 439-8346.

Martinez parades goalkeeper awards and justifies them with wonder save for Villa in Champions LeagueJimmy Carter, the former President of the United States and the founder of the idea of human rights protection in U.S. foreign policy, passed away at the age of 100. In a statement released on Sunday, December 30, Carter’s family announced his death, saying that he passed away peacefully surrounded by his loved ones. Carter is remembered as the 39th President of the United States, who took office in 1977. His presidency was marked by significant changes both in the U.S. and the Middle East. On one hand, the shadow of the Vietnam War loomed, while on the other, the rise of Islamist groups in the Middle East and the Soviet Union’s involvement in Afghanistan influenced U.S. foreign policy during Carter’s time in office. He was the first U.S. president to make the protection of human rights a cornerstone of American foreign policy, and during his administration, the Bureau of Human Rights was established within the U.S. Department of State. The news of Carter’s death has sparked widespread reactions. Current U.S. President Joe Biden described Carter as a “man of faith, humility, and principle.” According to Biden, “Carter worked with moral clarity and compassion to eliminate injustices, promote peace, and advance civil and human rights. He supported free and fair elections, built homes for the homeless, and was always committed to advocating for the voiceless.” Former President Donald Trump said, “Although I disagreed with him philosophically and politically, I knew that he truly loved our country and respected its values. He worked hard to make America a better place, and for that, I hold the highest respect for him.” Former President Barack Obama also remarked, “Carter, who was elected president under the shadow of the Watergate scandal, promised the American people that he would always tell the truth—and he did.” Jimmy Carter’s passing marks the end of an era in American politics. As one of the most distinguished figures in recent history, his legacy will be remembered for his unwavering commitment to human rights, peace, and social justice. His influence extends beyond his presidency and continues to inspire leaders and citizens around the world. While his political views were sometimes divisive, Carter’s integrity and dedication to public service earned him admiration across political divides. As the U.S. reflects on his life and contributions, his example of moral clarity and devotion to the greater good serves as a reminder of the power of principled leadership in shaping the course of history. Save my name, email, and website in this browser for the next time I comment. Δ

Public Health Director Theresa Arriola said none of the nine investigated restaurants on Guam that served food to Japanese tourists who reportedly showed symptoms of food poisoning when they came back to Japan early this month needed to be temporarily closed. The nine restaurants were based on a narrative survey that the Department of Public Health and Social Services, through its Division of Environmental Health, got from Holiday Tours Micronesia, the tour agency that handled the group of tourists. “The good news is all nine facilities did not warrant any means of closure,” Arriola told the Pacific Daily News. “That means the people of the nine establishments are still passing sanitation standards, and we didn’t have to close them.” While the investigation is still ongoing, the Public Health director reassured the public that based on findings so far, Guam’s restaurants remain safe. “I don’t have the list with me, but for the people of Guam, our restaurants are safe,” Arriola said. “After we left the establishments and conducted re-inspections, we know that they’re good to open for consumption, for the people of Guam.” These are the nine restaurants that Public Health investigated, along with the dates they were inspected: Arriola added that if food poisoning had occurred at local restaurants, there would likely be a rise in reports of illness from local residents. “People are eating there, and we have not heard of a cluster of illnesses,” Arriola said. “Outside of the students’ illness, if an establishment was the cause, then we should be seeing or hearing of local people getting sick.” This comes weeks after then acting Gov. Josh Tenorio tasked Public Health and the Guam Visitors Bureau to investigate the suspected food poisoning of 34 Japanese tourists. Japanese media outlets reported that 34 passengers, including high school students and their teachers, fell ill with suspected food poisoning symptoms after two flights from Guam arrived in Japan. Sixteen of the passengers were on Japan Airlines Flight 942, and 18 were on United Airlines Flight 873. Japanese officials suspected the illness was contracted while the group was on Guam, as passengers on both flights, traveling separately, reported similar symptoms. Arriola noted that the illness experienced by the Japanese tourists during their visit to Guam remains undetermined due to the lack of laboratory results from their doctor visits in Japan. Despite multiple requests, Public Health has not yet received the necessary lab results to identify the cause of the illness, she said. “It’s really up to the students, and in this case, their parents, because they’re minors, to give us their laboratory results from their doctor visits in Japan,” Arriola said. “Until we get that, there’s no conclusion of what actually made the kids sick.” Speculation continues about the cause of the illness, but there is no conclusive evidence linking it to any specific food or establishments. “There’s no conclusion that everybody ate at the same place or the same dish,” Arriola added. “Nobody will be sure until we get more data.”

White House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaign

New York Emerging Technology Advisory Board Publishes First Report Outlining Vision to Elevate Leadership in AIWhite House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaign

Raising Multilingual Children: A Global Parenting GuideNEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Light & Wonder, Inc. LNW resulting from allegations that Light & Wonder may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Light & Wonder securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=29678 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. WHAT IS THIS ABOUT: On September 24, 2024, the Las Vegas Review-Journal published an article entitled "Slot manufacturer scores major win against Las Vegas-based rival." It stated that "Aristocrat Technologies Inc.'s request for a preliminary injunction in its trade-secret and copyright infringement lawsuit against Light & Wonder" had been granted, and that the "order prohibits [Light & Wonder] from the ‘continued or planned sale, leasing, or other commercialization of Dragon Train,' which Aristocrat claims uses intellectual property developed for its Dragon Link and Lightning Link games." On this news, the price of Light & Wonder common stock fell 19.49% on September 24, 2024. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.